Seletracetam

Drug Profile

Seletracetam

Alternative Names: UCB 44212

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator UCB
  • Class Antiepileptic drugs; Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Epilepsy

Most Recent Events

  • 10 Oct 2006 Interim results from two phase IIa clinical trials (N01191 and N01192) in patients with epilepsy have been added to the adverse events and Epilepsy therapeutic trials sections
  • 21 Nov 2005 Data presented at the 26th International Epilepsy Congress (IEC-2005) have been added to the Epilepsy and seizure disorders pharmacodynamics section ,,
  • 18 Apr 2005 Data presented at the 9th International Congress of Parkinson's Disease and Movement Disorders (PDMD-2005) have been added to the Parkinson's disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top